Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19

An interesting potential treatment? I am not quite so sure how practical this would be, but the results are interesting.

…”adoptive cellular therapy using donor-derived virus-specific T cells. Here we show that SARS-CoV-2-exposed blood donations contain CD4 and CD8 memory T cells specific for SARS-CoV-2 spike, nucleocapsid and membrane antigens…… These T cells can be rapidly expanded using GMP-compliant reagents for use as a therapeutic product. ” .,Read More

Full length article OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath

Highlights • Life cycle of SARS-CoV-2 in host cell have been demonstrated. • CT scan and RT-PCR are very helpful in diagnosis of COVID-19 infection. • Antiviral, antimalarial, antimicrobial and ROCK inhibitors were found very effective. • Dietary supplements […]

Click here to view original web page at Full length article OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath

Phase 3 trial for Moderna COVID-19 vaccine begins amid US summer surge

Today marks the start of the phase 3 trial of Moderna’s COVID-19 vaccine candidate. The COVE trial (Coronavirus Efficacy) will enroll 30,000 people at 89 sites across the country, with half the recipients receiving two shots of the vaccine […]

Click here to view original web page at Phase 3 trial for Moderna COVID-19 vaccine begins amid US summer surge

Late-stage coronavirus vaccine trial starts today in the US

The first large phase 3 trial of a candidate coronavirus vaccine in the U.S. began today (July 27). The biotech company Moderna is conducting the phase 3 trial, called COVE (Coronavirus Efficacy), in collaboration with the National Institute of […]

Click here to view original web page at Late-stage coronavirus vaccine trial starts today in the US

Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients

Abstract We analyzed the bacterial communities of the nasopharynx in 40 SARS-CoV-2 infected and uninfected patients. All infected patients had a mild COVID-19 disease. We did not find statistically significant differences in either bacterial richness and diversity or composition. […]

Click here to view original web page at Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.

Spike glycoprotein, a class I fusion protein harboring the surface of SARS-CoV-2 (SARS-CoV-2S), plays a seminal role in the viral infection starting from recognition of the host cell surface receptor, attachment to the fusion of the viral envelope with […]

Click here to view original web page at Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.